{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cellulitis-acute/diagnosis/diagnosis/","result":{"pageContext":{"chapter":{"id":"8625eea6-53ec-5348-befa-a609ea64590f","slug":"diagnosis","fullItemName":"Diagnosis","depth":2,"htmlHeader":"<!-- begin field d9605932-7c49-477b-ab79-aa0e27621942 --><h2>How should I diagnose cellulitis?</h2><!-- end field d9605932-7c49-477b-ab79-aa0e27621942 -->","summary":"","htmlStringContent":"<!-- begin item 3f598aab-4a4b-4b48-9e88-372441bf24d7 --><!-- begin field c911cd43-eed8-4663-99d4-d7a854b45b0d --><ul><li><strong>Take a history.</strong><ul><li>Ask about:<ul><li>Symptoms experienced, including duration and severity.</li><li>Recent trauma to the skin, for example, a bite, burn, or laceration.</li><li>Underlying <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/background-information/risk-factors/\">comorbidities</a> (such as diabetes mellitus) that predispose to infection.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/background-information/causes/\">Predisposing conditions</a> or environmental conditions which may increase the likelihood of specific pathogens (such as salt or fresh water exposure).</li></ul></li></ul></li><li><strong>Examine the person.</strong> <ul><li>Cellulitis is more commonly seen in the lower limbs and usually affects one limb (bilateral leg cellulitis is very rare). Typical features include:<ul><li>An acute onset of red, painful, hot, swollen, and tender skin, that spreads rapidly.</li><li>Fever, malaise, nausea, shivering, and rigors — these may accompany or even precede skin changes.</li></ul></li><li>On examination:<ul><li>There is usually an obvious skin break where the infecting organism may have entered, such as a wound, macerated skin, fungal skin infection, an ulcer, or a concomitant skin disorder (such as atopic eczema).</li><li>There may be diffuse redness or a well-demarcated edge that can be marked with a pen in order to monitor progress.</li><li>Blisters and bullae may be seen. Occasionally, there may be inflamed regional lymph nodes or associated lymphangitis, characterized by the presence of red, linear streaks spreading proximally from the area of cellulitis. If swelling is significant, the skin surface may develop a <em>peau d’orange</em> appearance. </li><li>Severe cellulitis can lead to ulceration and more deep-seated tissue damage.</li></ul></li><li>Assess for underlying <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/background-information/risk-factors/\">risk factors</a> (such as lymphoedema and leg oedema).</li><li>Exclude <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/diagnosis/differential-diagnosis/\">differential diagnoses</a> (such as erysipelas, contact allergic dermatitis, deep vein thrombosis, and cutaneous abscess)<strong>.</strong></li></ul></li><li><strong>If cellulitis is diagnosed, categorize the severity using the</strong> <strong>Eron classification system, </strong>to help guide <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/management/\">management</a> decisions.<ul><li>Class I — there are no signs of systemic toxicity and the person has no uncontrolled comorbidities.</li><li>Class II — the person is either systemically unwell or systemically well but with a comorbidity (for example peripheral arterial disease, chronic venous insufficiency, or morbid obesity) which may complicate or delay resolution of infection.</li><li>Class III — the person has significant systemic upset, such as acute confusion, tachycardia, tachypnoea, hypotension, or unstable comorbidities that may interfere with a response to treatment, or a limb-threatening infection due to vascular compromize.</li><li>Class IV — the person has sepsis or a severe life-threatening infection, such as necrotizing fasciitis.</li></ul></li><li><strong>Investigations are not usually necessary </strong>but may be considered in certain cases and/or performed in secondary care settings, for example:<ul><li>A swab for culture — if there is an open wound, penetrating injury, drainage, or an obvious portal for microbial entry, exposure to water borne-organisms, an infection acquired outside the UK or in severe cellulitis.<ul><li>Be aware that swab cultures, especially those of chronic wounds or ulcers, are commonly polymicrobial or colonized with multidrug-resistant pathogens that are not involved in the aetiology of underlying cellulitis.</li></ul></li><li>Ultrasonography — for distinguishing nonpurulent cellulitis from cellulitis with underlying abscess and for identifying drainable fluid collection, particularly if the clinical assessment is indeterminate.</li><li>A skin biopsy — if there is doubt about the diagnosis and to help identify any unusual pathogens in people who are unresponsive to initial treatment.</li><li>White blood cell count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) — to detect acute inflammation. Although nonspecific, most people with cellulitis will have elevations in white blood cell count, ESR, and CRP levels. Normal results make a diagnosis of cellulitis less likely.</li><li>Other relevant tests — to exclude <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/diagnosis/differential-diagnosis/\">differential diagnoses</a> (such as deep vein thrombosis, septic arthritis, and acute gout).</li></ul></li></ul><!-- end field c911cd43-eed8-4663-99d4-d7a854b45b0d --><!-- end item 3f598aab-4a4b-4b48-9e88-372441bf24d7 -->","topic":{"id":"c0841d82-0a64-5b27-81dc-9a825d85f1bf","topicId":"6db61277-29ef-49cc-bad1-d0d78d0afc10","topicName":"Cellulitis - acute","slug":"cellulitis-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"84376fdb-da2b-561d-bb40-28b5b1a7e975","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bdf35905-533d-5cb1-bd18-9c1575427a25","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d6c8c4bd-9395-5840-83c7-67ddfeabdf85","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"59d003f6-dd50-5136-b5c2-c2ea4e4b6f01","slug":"changes","fullItemName":"Changes"},{"id":"f79ca51e-9432-56b1-95de-92ed6133be2b","slug":"update","fullItemName":"Update"}]},{"id":"05002b30-8200-5ccf-b9da-7c96acdb65bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fefb70b6-1d32-5e70-afc6-291fa40b3137","slug":"goals","fullItemName":"Goals"},{"id":"cf84220a-f381-5ca1-aa76-ffb99c4959f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aa32cbb7-29d6-58b6-bcde-7702767672ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7e039433-2afe-5980-93f0-c20c41976610","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d1411fdd-dc83-5f20-9fa4-ad67b69c195a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ce40a600-51e8-5b3a-86c2-d127f03c16eb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff60c523-3d6f-5766-8508-98e8cdcf08f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e8cfe4a-13f2-573c-ab45-7231016746c4","slug":"definition","fullItemName":"Definition"},{"id":"2b7befe3-0fef-5d4e-b00d-bad6742fb93c","slug":"causes","fullItemName":"Causes"},{"id":"96971948-f52b-561c-84f8-8600f3eff2d4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4749dc8a-3f24-5e65-a0a3-5d7665ef3085","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ad3d41f6-595b-505c-b020-918f0e086d3f","slug":"complications","fullItemName":"Complications"},{"id":"82ccb916-06d4-5b29-91e4-90005f3db942","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7305e6df-9b2c-5584-9412-54564432e382","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8625eea6-53ec-5348-befa-a609ea64590f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"273b1216-536e-59b4-8c39-547a97824ffa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"68b86e3a-ee13-5ccd-9df0-a5c70c553251","fullItemName":"Management","slug":"management","subChapters":[{"id":"195394ca-067a-5cf3-bc4d-52a189d2cba6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"78de19b8-8e80-551f-8112-456ce2e25bb0","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"73060223-dd90-59da-bae3-c706b5d24298","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"83f47301-e112-5f78-a79a-5c03a9de9537","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"b7240858-fbcc-5f20-8dcd-19f0b7221ac4","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07828388-33ed-5e04-90b7-28a76fa26c6e","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"4600d0c1-4cd1-51ee-87a0-b660f0fa2165","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0c0b7a3f-11e4-5b00-bd21-b66e49f9ad77","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"29987f8b-20b6-5c1f-8d23-183b415a04fb","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"4b09dc1a-8268-50d6-a164-227a73b3556e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d49b86e1-77b2-58e6-82c0-ea0aa7ee74ed","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fe910063-69df-5218-bb78-36f5863db2a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"129f5233-2934-55ad-a561-4eb37861dc10","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"74d5b6b4-ef9d-5fc4-b41b-656b81a7ded8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"44402335-ffeb-5e14-9e77-bb8278ef43d6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"04d7d640-f586-53d9-ac59-804c10dd593d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c50af1ff-f157-5023-92b4-aa07b1c28d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7305e6df-9b2c-5584-9412-54564432e382","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"6658db21-c94a-5b7c-89b3-484deef2405b","slug":"basis-for-recommendation-809","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 9691590d-ec28-445d-b0d9-d0000904659e --><h3>Basis for recommendation</h3><!-- end field 9691590d-ec28-445d-b0d9-d0000904659e -->","summary":null,"htmlStringContent":"<!-- begin item 809e3e37-bed0-43fc-8945-5eb9114ad1e8 --><!-- begin field ac7b6848-bd4a-4859-be00-5e52b15db916 --><p>These recommendations are based largely on the Clinical Resource Efficiency Support Team (CREST) <em>Guidelines on the management of cellulitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>], the Primary Care Dermatology Society (PCDS) guideline <em>Cellulitis, erysipelas, and necrotising fasciitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">PCDS, 2018</a>], a Cochrane systematic review on <em>Interventions for the prevention of recurrent erysipelas and cellulitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Dalal, 2017</a>], and on expert opinion in review articles on cellulitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Raff, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Shriner, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Bystritsky, 2018</a>].</p><ul><li>The diagnosis of cellulitis can usually be made on history and examination alone, although investigations may be considered in certain cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Raff, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Dalal, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Shriner, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Bystritsky, 2018</a>]. Experts advise that:<ul><li>The value of microbiological culture in the management of cellulitis is limited. Needle aspirations taken from the infected skin areas and then cultured are positive for bacterial growth in only 10% of cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>]. A higher yield is noticed in surgically‐removed full‐thickness skin biopsies or other tissue specimens from the lesion, with successful bacterial growth in 20–30% of cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Dalal, 2017</a>].</li><li>Swab cultures, especially those of chronic wounds or ulcers, are commonly polymicrobial or colonized with multidrug-resistant pathogens that are not involved in the aetiology of underlying cellulitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Raff, 2016</a>].</li><li>Blood cultures are rarely positive, with only 2–4% of cultures showing positive bacterial growth [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Dalal, 2017</a>], and contaminants may outnumber pathogens [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>].</li><li>If bullae or abscesses form, culturing the fluid from inside these lesions yields an organism in more than 90% of cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Raff, 2016</a>].</li></ul></li></ul><!-- end field ac7b6848-bd4a-4859-be00-5e52b15db916 --><!-- end item 809e3e37-bed0-43fc-8945-5eb9114ad1e8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}